" class="no-js "lang="en-US"> Transgene - Medtech Alert
Monday, June 17, 2024
Transgene | Pharmtech Focus

Transgene

About Transgene

Transgene

Cancer immunotherapy

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing novel immunotherapies for the treatment of cancer.

Related Story

Transgene and BioInvent Report Positive Phase Ia Data on Oncolytic Virus BT-001 in Solid Tumors

May 25 2023

Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International […]

Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors

March 10 2023

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, […]

Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine

November 23 2021

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment […]